logo
Plus   Neg
Share
Email

Dr. Reddy's Begins EUA Process In India For Sputnik V Vaccine - Quick Facts

Dr. Reddy's Laboratories Ltd. (RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization of the vaccine candidate, Sputnik V. The company will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 21st February 2021.

Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, is the world's first registered vaccine against COVID-19 based on the human adenoviral vector platform. In September, Dr. Reddy's partnered with the Russian Direct Investment Fund to conduct the clinical trials of the Sputnik V and for its
distribution rights in India. Sputnik V has showed an efficacy rate of 91.6% in the interim analysis of the phase 3 clinical trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT